AuthorisedTherapeutic use (Phase IV)Interventional

EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales ("RAPID")

This study, called "RAPID," is for hospital patients with serious infections like bloodstream infections or pneumonia, particularly infections caused by specific bacteria (Pseudomonas aeruginosa or carbapenemase producing Enterobacterales) that are often difficult to treat. Researchers are comparing a newer antibiotic, Zavicefta, given with the help of fast diagnostic tests, against the usual antibiotics and diagnostic methods. The main goal is to see if Zavicefta and quick test results can improve survival and overall health after 14 days. It also looks at how quickly patients recover, how long they stay in hospital, and if new problems or side effects develop. This study aims to find better and faster ways to manage these challenging infections.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

National University Of Singapore

Enrolment target

Start

29 Apr 2026

Bloodstream Infection, Ventilator Associated Pneumonia and Hospital-Acquired Pneumonia

What is this study about?

This study is called the "RAPID" trial, and it's looking into new ways to treat very serious infections that people can get in hospital. These infections include bloodstream infections (when bacteria get into your blood), or certain types of pneumonia, which is a lung infection. These infections are often caused by specific types of bacteria that are hard to treat with common antibiotics.

The trial is comparing the usual ways doctors treat these infections with a new approach. This new approach uses a specific antibiotic called Zavicefta along with very fast diagnostic tests. These quick tests help doctors know sooner exactly what type of bacteria is causing the infection, so they can choose the best treatment right away. The aim is to see if this faster, targeted treatment can help patients get better quicker and improve their chances of survival.

Researchers will closely follow patients in the study to check if the new treatment leads to better outcomes, such as a faster recovery, spending less time in intensive care or hospital, and fewer complications. They are particularly interested in how patients are doing 14 days after starting treatment.

Key takeaways

This study compares a new antibiotic approach (Zavicefta + rapid tests) to standard care for serious hospital infections.
It focuses on bloodstream infections and pneumonia caused by hard-to-treat bacteria.
The main goal is to see if the new approach improves patient survival and overall health.
Participants' health will be closely monitored for 14 to 60 days.
Joining is voluntary, and you can withdraw at any time.

Who may be eligible?

To be part of this study, you would need to be at least 18 years old. Both men and women can take part.

You would also need to have a serious bacterial infection that you got while in hospital. This could be an infection in your blood, or a type of pneumonia (a lung infection) that you developed while staying in hospital or when you were on a breathing machine.

Importantly, your infection would need to be caused by certain types of bacteria (called Pseudomonas aeruginosa or carbapenemase producing Enterobacterales) that are known for being difficult to treat with standard antibiotics. Your doctor would be able to check if your infection fits these criteria.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I 18 years old or older?
Do I have a serious infection I caught in the hospital (like a bloodstream infection or pneumonia)?
Has my doctor told me my infection is caused by specific bacteria that are hard to treat with usual antibiotics?
Am I currently receiving medical care in a hospital setting?

Answer every question to see your result.

What does participation involve?

If you join the study, you would receive either the new antibiotic, Zavicefta, or the standard antibiotics that your doctors would normally use for your type of infection. The choice of treatment would be decided by chance, like flipping a coin, so neither you nor your doctor would choose.

Throughout the study, doctors and nurses would regularly check your health. This would include looking at your symptoms, taking blood tests, and performing other tests relevant to your infection. The study would closely monitor how you respond to the treatment over several weeks, especially during the first 14 days. They would also keep track of things like how long you stay in hospital, if you need a breathing machine, and your general health for up to 60 days after your infection was first identified.

Potential risks and benefits

Taking part in this study might offer a potential benefit if Zavicefta, combined with rapid diagnostics, proves to be a more effective or faster-acting treatment for your serious infection. However, like all medications, Zavicefta and standard antibiotics can have side effects. Your medical team will explain any potential risks and closely monitor you for any problems. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Italy

Common questions

What is Zavicefta?

Zavicefta is an antibiotic, a type of medicine used to treat serious bacterial infections. This study is looking at how it performs against difficult-to-treat bacteria.

Why is this study called 'RAPID'?

It's called RAPID because it's looking at whether using fast diagnostic tests to identify bacteria quickly can help doctors choose the best antibiotic treatment, like Zavicefta, sooner.

What kind of infections is this study looking at?

It's for serious infections you get in hospital, like bloodstream infections or pneumonia, especially if they are caused by specific bacteria that are hard to treat with usual medicines.

What will happen if I join the study?

You will receive either the study antibiotic (Zavicefta) or standard treatment, and your health will be carefully monitored for several weeks to see how well the treatment works.

Can I leave the study if I change my mind?

Yes, you can choose to leave the study at any point, and your medical care will not be affected.